References
- Bi HC, Law FC, Zhong GP, Xu CS, Pan Y, Ding L, Chen X, Zhao LZ, Xu Q, Huang M. Study of tanshinone IIA tissue distribution in rat by liquid chromatography-tandem mass spectrometry method. Biomedicine and Chromatography 2007; 21: 473–479
- Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharmacology Research 1993; 10: 1093–1095
- Don MJ, Shen CC, Syu WJ, Ding YH, Sun CM. Cytotoxic and aromatic constituents from Salvia miltiorrhiza. Phytochemistry 2006; 67: 497–503
- Hao H, Wang G, Cui N, Li J, Xie L, Ding Z. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Medica 2006a; 72: 1311–1317
- Hao H, Wang G, Li P, Li J, Ding Z. Simultaneous quantification of cryptotanshinone and its active metabolite tanshinone IIA in plasma by liquid chromatography/tandem mass spectrometry (LC-MS/MS). Journal of Pharmacology and Biomedical Analysis 2006b; 40: 382–388
- Hori R, Okumura K, Yoshida H. Binding of basic drugs to rat lung mitochondria. Pharmacology Research 1987; 4: 142–146
- Hur JM, Shim JS, Jung HJ, Kwon HJ. Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Experimental Molecular Medicine 2005; 37: 133–137
- Jin DZ, Yin LL, Ji XQ, Zhu XZ. Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression. European Journal of Pharmacology 2006; 549: 166–172
- Kang BY, Chung SW, Kim SH, Ryu SY, Kim TS. Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 2000; 49: 355–361
- Luo X, Xu YH, Chen B, Gu LQ, Huang M, Liu PQ. Solubilization on cryptotanshinone by hydroxypropyl-b-cyclodextrin and preparation of their inclusion compound. Zhongguo Zhongyao Zazhi 2005; 30: 1328–1331
- Nishiura A, Murakami T, Higashi Y, Yata N. Role of phosphatidylserine in the cellular and subcellular lung distribution of quinidine in rats. Pharmacology Research 1988; 5: 209–213
- Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metabolism Reviews 2007; 39: 17–43
- Song M, Hang TJ, Zhang Zh X, Du R, Chen J. Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technology and Biomedical Life Sciences 2005; 827: 205–209
- Wang AM, Sha SH, Lesniak W, Schacht J. Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrobial Agents and Chemotherapy 2003; 47: 1836–1841
- Xie MZ, Shen ZF. [Absorption, distribution, excretion and metabolism of cryptotanshinone]. Yao Xue Xue Bao 18 1983; 90–96
- Xue M, Cui Y, Wang HQ, Luo YJ, Zhang B, Zhou ZT. [Pharmacokinrtics of cryptotanshinone and its metabolite in pigs]. Yao Xue Xue Bao 34 1999; 81–84
- Zhang J, Huang M, Guan S, Bi HC, Pan Y, Duan W, Chan SY, Chen X, Hong YH, Bian JS, Yang HY, Zhou S. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. Journal of Pharmacology and Experimental Therapy 2006; 317: 1285–1294
- Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. Journal of Clinical Pharmacology 2005; 45: 1345–1359